Q3 2026 Medpace Holdings, Inc. Earnings Conference Call - MEDPACE HOLDINGS INC

Explicit Guidance:

• 2026 Full-Year Revenue: Revised upward to a range of $2.835 billion to $2.855 billion, reflecting 12% to 12.8% growth over 2025 revenue ($2.53 billion).
• 2026 Full-Year EBITDA: Revised upward to a range of $638 million to $652 million, representing 14.4% to 16.9% growth over 2025 EBITDA ($557.7 million).
• 2026 Full-Year Net Income: Forecast in the range of $514 million to $524 million.
• 2026 Effective Tax Rate: Assumed to be 19% to 19.5%.
• 2026 Interest Income: Assumed at $22.9 million.
• 2026 Diluted Weighted Average Shares: Assumed at 28.6 million with no share purchases factored into the guidance.
• 2026 Diluted EPS: Expected to be in the range of $17.97 to $18.32.
• 2027 Guidance: Deferred until Q4 reporting in February 2027; no specific numbers provided currently, noting consensus estimates appear to be in the "right range."
• 2027 Operating Costs: A new expansion in Cincinnati will add approximately $20 million in operating costs in 2027.

Business-Segment Outlook:

• Backlog Conversion: Approximately $1.99 billion of the $3.2 billion ending backlog (as of Sept 30, 2026) is projected to convert to revenue in the next 12 months.
• Therapeutic Mix: Anticipated shift toward traditional oncology (largest area) and away from metabolic demand for current awards; however, pending RFPs show significant metabolic opportunities.
• Customer & Client Strategy: Focus remains on full-service engagements; open to front-end only projects but not functional service provider (FSP) carve-outs. No major shift in client decision timelines; projects moving faster than last year.
• Win Rate & Initiatives: Previous process adjustments made late 2025 to address win rates are showing success; Q4 is expected to be another record quarter for awards if cancellation patterns remain normal.
• Large Pharma: Revenue growth in this segment is primarily driven by existing biotech clients acquired by large pharma rather than direct new logo acquisition.

Market and Competitive Outlook:

• Competitive Environment: Described as "normalized" following "crazy approaches" of previous years; focus is on quality and deliverables rather than price wars.
• Demand Trends: "High-quality" RFP activity and strong initial award notifications; total dollar value of pending opportunities is up significantly.
• Pricing: No indication of significant price tightening or inflationary pricing power yet; pricing remains stable in a normalized market.
• RFP Activity: While RFP numbers have dipped slightly, the quality and total value of pending decisions are high, with award decisions moving at a normal pace.

Macro / Industry Outlook:

• Cancellations: Primary driver for future outlook; cancellations are now attributed mainly to product failure (safety signals, lack of efficacy) and prioritization rather than direct funding constraints.
• Funding: No current evidence that funding levels are the main driver of cancellations.
• Labor Market: Turnover remains exceptionally low; no abnormal pressures on salaries, wages, or benefits expected for 2027.
• FX: 2026 guidance is based on foreign exchange rates as of September 30, 2026.

Strategic Initiatives:

• Cincinnati Expansion: Significant expansion going online; expected to add $20 million in operating costs in 2027.
• Share Repurchase: Board terminated the previous authorization and approved a new $1 billion share repurchase authorization effective October 20, 2026 (note: no purchases assumed in 2026 guidance).
• Capacity & Hiring: Headcount growing at a high-single-digit sequential rate, with revenue outpacing growth in utilization.

Risks and Headwinds to Outlook:

• Cancellation Volatility: High uncertainty regarding Q4 cancellations is the primary reason for deferring 2027 guidance; unexpected "product failure" or safety signals are random and difficult to predict.
• Margin Volatility: Direct fee margins face quarter-to-quarter volatility due to ASC 606 timing and project mix; margins are expected to remain strong in Q4 but face a headwind in 2027 due to the Cincinnati expansion absorption.
• Pipeline Execution: Q4 awards are critical for 2027 revenue; failure to maintain win rates or an unexpected surge in cancellations could negatively impact 2027 expectations.

Management Tone on the Future:

• Confidence Level: Generally optimistic regarding bookings and win rates ("strong," "high-quality," "improving month to month").
• Hedging: Highly cautious regarding 2027 guidance due to unpredictable cancellation patterns; explicitly avoids issuing a guide that might prove inaccurate.
• Shift in Narrative: Moved from focusing on "book-to-bill" metrics to emphasizing award growth and trailing 12-month awards; expressed relief that cancellation patterns are manageable but remain the key variable.
• 2027 Expectations: Believes growth profile will improve relative to recent years as the impact of prior cancellations fades, though the rate is expected to be lower than historical peaks.

Miscellaneous:

• Pass-Through Mix: Expected to remain stable around 40% to 40.5% for the remainder of the year and potentially step up in Q4.
• Direct Fee Margins: Q3 margins benefited from lower reimbursable costs; margins are expected to be sustainable in Q4 despite headwinds in 2027.
• EBITDA Margin: Q3 2026 margin was 24%; YTD margin was 22.3%.